Dual-Drug Chitosan Hydrogel Loaded with Metformin and Cefazolin for Antibacterial, Anti-Inflammatory and Antioxidant Treatment of Drug-Resistant Bacteria-Infected Skin Wounds.
- 1College of Modern Agriculture and Bioengineering, Shangluo University, Shangluo 726000, China.
- 2College of Chemical Engineering and Modern Materials, Shangluo University, Shangluo 726000, China.
- 3Shaanxi Xiangju Pharmaceutical Group Company Limited, Shangluo 726000, China.
Abstract
Bacterial-infected skin wounds, especially those caused by drug-resistant pathogens accompanied by persistent inflammation, remain a major clinical therapeutic challenge. Rising antimicrobial resistance compromises the therapeutic effect of conventional single-agent antibiotics, creating an urgent demand for novel wound therapeutics that integrate bactericidal potency, immunomodulation and tissue regeneration capacity. In this work, an injectable multifunctional chitosan-based hydrogel (C@MC) was developed, which simultaneously incorporates metformin hydrochloride (as a potential antibiotic adjuvant) and cefazolin sodium (as a β-lactam class antibacterial drug). The optimized C@MC possesses interconnected three-dimensional pores with an initial storage modulus of ~0.83 kPa (C@MC₃₆₀), featuring desirable mechanical strength, injectability, tissue adhesion and dual pH/glucose-responsive sustained drug release. In vitro evaluations revealed the dose-dependent bactericidal activity of C@MC against Staphylococcus aureus (S. aureus), Escherichia coli (E. coli) and New Delhi metallo-β-lactamase-1-producing E. coli (NDM-1 E. coli, resistant bacteria). The highest drug-laden group nearly eliminated all wound bacteria in vitro. It scavenged reactive oxygen species (ROS) to lower cellular MDA levels and suppress pro-inflammatory TNF-α and IL-6 in LPS-stimulated RAW 264.7 macrophages. In full-thickness mouse wounds infected with NDM-1 E. coli, C@MC₃₆₀ achieved nearly complete wound closure, with only a 4.2% residual wound area on day 14, accompanied by suppressed inflammatory infiltration and accelerated wound regeneration. This dual-drug hydrogel integrates antibiotic potentiation, anti-inflammation and antioxidation, providing an intervention regimen for skin wounds infected with drug-resistant bacteria.
Related
- Experimental and computational evaluation of antiproliferative, antioxidant, and antibacterial activities of Commiphora terebinthina aerial parts
- Assessment of antibacterial and antioxidant potentials of Aspergillus fumigatus crude extract, the isolated endophyte from Centella asiatica (L.) urban supported by molecular docking
- Effect of metformin treatment on brain 18F-FDG uptake: a translational study
- Effectiveness of metformin as initial treatment on the metabolic profile of Saudi patients newly diagnosed with type 2 diabetes mellitus : A prospective observational study
- An ultrasound-switchable hydrogel enables sequential antibacterial and anti-inflammatory therapy for infected diabetic wounds
BibTeX
@article{zhang2026dualdrug,
title = {{Dual-Drug Chitosan Hydrogel Loaded with Metformin and Cefazolin for Antibacterial, Anti-Inflammatory and Antioxidant Treatment of Drug-Resistant Bacteria-Infected Skin Wounds.}},
author = {Yilin Zhang and Jie Cao and Yong Yan and Zhaoyang Li and Haiqiang Ren and Chenxiong Xu and Chengfang Qiao and Wei Zhou},
journal = {Gels (Basel, Switzerland)},
year = {2026},
month = sep,
doi = {10.3390/gels12100876},
url = {https://europepmc.org/article/MED/42929911},
note = {CC BY},
}
RIS
TY - JOUR
TI - Dual-Drug Chitosan Hydrogel Loaded with Metformin and Cefazolin for Antibacterial, Anti-Inflammatory and Antioxidant Treatment of Drug-Resistant Bacteria-Infected Skin Wounds.
AU - Yilin Zhang
AU - Jie Cao
AU - Yong Yan
AU - Zhaoyang Li
AU - Haiqiang Ren
AU - Chenxiong Xu
AU - Chengfang Qiao
AU - Wei Zhou
PY - 2026
DA - 2026/09/28
JO - Gels (Basel, Switzerland)
DO - 10.3390/gels12100876
UR - https://europepmc.org/article/MED/42929911
AB - Bacterial-infected skin wounds, especially those caused by drug-resistant pathogens accompanied by persistent inflammation, remain a major clinical therapeutic challenge. Rising antimicrobial resistance compromises the therapeutic effect of conventional single-agent antibiotics, creating an urgent demand for novel wound therapeutics that integrate bactericidal potency, immunomodulation and tissue regeneration capacity. In this work, an injectable multifunctional chitosan-based hydrogel (C@MC) was developed, which simultaneously incorporates metformin hydrochloride (as a potential antibiotic adjuvant) and cefazolin sodium (as a β-lactam class antibacterial drug). The optimized C@MC possesses interconnected three-dimensional pores with an initial storage modulus of ~0.83 kPa (C@MC₃₆₀), featuring desirable mechanical strength, injectability, tissue adhesion and dual pH/glucose-responsive sustained drug release. In vitro evaluations revealed the dose-dependent bactericidal activity of C@MC against Staphylococcus aureus (S. aureus), Escherichia coli (E. coli) and New Delhi metallo-β-lactamase-1-producing E. coli (NDM-1 E. coli, resistant bacteria). The highest drug-laden group nearly eliminated all wound bacteria in vitro. It scavenged reactive oxygen species (ROS) to lower cellular MDA levels and suppress pro-inflammatory TNF-α and IL-6 in LPS-stimulated RAW 264.7 macrophages. In full-thickness mouse wounds infected with NDM-1 E. coli, C@MC₃₆₀ achieved nearly complete wound closure, with only a 4.2% residual wound area on day 14, accompanied by suppressed inflammatory infiltration and accelerated wound regeneration. This dual-drug hydrogel integrates antibiotic potentiation, anti-inflammation and antioxidation, providing an intervention regimen for skin wounds infected with drug-resistant bacteria.
SN - 2310-2861
ER -